TM
MYGN icon

Torren Management’s Myriad Genetics MYGN Stock Holding History

Torren Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,716
Closed -$10.6K – 1273
2025
Q4 		$10.6K Buy
+1,716
New +$12.4K 0.01% 752

Other funds holding MYGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Torren Management's MYGN Position: Q1 2026 in Review

Torren Management sold out of Myriad Genetics (MYGN) in Q1 2026, closing a stake of 1,716 shares — an estimated $10.6K sold.

Torren Management first reported a position in MYGN in Q4 2025 and held it in 1 quarter. The position peaked at $10.6K in Q4 2025. 202 funds tracked by Wall St. Rank hold MYGN as of Q1 2026.

  • Torren Management reported no remaining Myriad Genetics position as of Q1 2026 after selling out during the quarter.
  • Torren Management sold 1,716 Myriad Genetics shares in Q1 2026, an estimated $10.6K.
  • Torren Management first reported a position in Myriad Genetics in Q4 2025 and held it in 1 quarter.
  • Torren Management's Myriad Genetics position peaked at $10.6K in Q4 2025.
  • 202 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2026.

Based on Torren Management's 13F filing for Q1 2026, filed 30 Apr 2026.